Keyphrases
Clinical Practice
100%
IgA Nephropathy (IgAN)
100%
Sparsentan
100%
Proteinuria
41%
High Risk
33%
Blood Pressure
25%
Reduced Kidney Function
25%
Endothelin-1 (ET-1)
25%
Kidney
16%
Immune System
16%
Angiotensin II (Ang II)
16%
Irbesartan
16%
Glomerular Filtration Barrier
8%
Kidney Disease
8%
Immunosuppressive Therapy
8%
Kidney Failure
8%
Clinical Practice Guidelines
8%
Clinical Trials
8%
Clinical Application
8%
Older Adults
8%
Disease Progression
8%
Primary Glomerulonephritis
8%
Immune Complex
8%
Standard of Care
8%
Patient Selection
8%
Single Molecule
8%
Disease Risk
8%
U.S. Food
8%
Active Control
8%
Immunosuppressive Agents
8%
Mesangium
8%
Risk of Progression
8%
Plain Language Summary
8%
Glomerular Injury
8%
Practical Guidance
8%
Accelerated Approval
8%
Angiotensin Receptor Antagonists
8%
Kidney Disease Improving Global Outcomes
8%
Causes of Damage
8%
Persistent Proteinuria
8%
Medicine and Dentistry
Immunoglobulin A Nephropathy
100%
Sparsentan
100%
Proteinuria
50%
Kidney Function
25%
Blood Pressure
25%
Nephropathy
16%
Side Effect
16%
Endothelin 1
16%
Angiotensin II
16%
Immune System
16%
Irbesartan
16%
Renal Failure
8%
Immunosuppressive Treatment
8%
Disease Exacerbation
8%
Clinical Trial
8%
Glomerulonephritis
8%
Immunoglobulin A
8%
Receptor
8%
Immunosuppressive Drug
8%
Physician
8%
Medicine
8%
Angiotensin Receptor Antagonist
8%
Antigen Antibody Complex
8%
Glomerular Filtration Barrier
8%
Endothelin
8%
Diseases
8%
Pharmacology, Toxicology and Pharmaceutical Science
Immunoglobulin A Nephropathy
100%
Sparsentan
100%
Proteinuria
50%
Immunosuppressive Agent
16%
Kidney Disease
16%
Side Effect
16%
Endothelin 1
16%
Angiotensin II
16%
Irbesartan
16%
Kidney Failure
8%
Disease Exacerbation
8%
Clinical Trial
8%
Receptor
8%
Immunoglobulin A
8%
Endothelin
8%
Angiotensin Receptor Antagonist
8%
Glomerulonephritis
8%
Diseases
8%